Go to the list of all blogs
Allana's Avatar
published in Blogs
Sep 11, 2026
TickeronGET DAILY SIGNALS
Why Is Omada Health (OMDA) Stock Down -7.63% Today?

Why Is Omada Health (OMDA) Stock Down -7.63% Today?

Key Takeaways

  • OMDA shares fell 7.63% to $19.86, down $1.64 from the prior session's close of $21.50.
  • The decline extended a multiweek pullback that has carried the stock roughly 18% below its August highs.
  • Markets pointed to post–Investor Day profit-taking after long-term targets failed to sustain Thursday's early gains.
  • Elevated short interest and a steady stream of disclosed insider selling weighed on sentiment.
  • Broader weakness in growth-oriented digital health and healthcare technology names compounded the move.
  • Traders are now watching technical support near $20 and the company's next earnings report in early November.

Opening Summary

Omada Health, Inc. (OMDA), a South San Francisco–based provider of virtual care programs for chronic conditions such as diabetes, hypertension, and musculoskeletal issues, traded sharply lower on Friday. The stock dropped 7.63% to $19.86 during the session, compared with a prior closing price of $21.50, as investors took profits following the company's first Investor Day and a broader risk-off tone pressured smaller healthcare technology names.

Post–Investor Day "Sell the News"

The most direct catalyst behind the slide was a classic "sell the news" reaction. On Thursday, OMDA held its inaugural Investor Day and unveiled updated long-term financial targets, including annual revenue growth of at least 20%, an adjusted gross margin of 80%, and an adjusted EBITDA margin of 30%. Shares initially gained on the announcement but closed well off session highs, and that momentum reversed sharply on Friday as traders locked in gains after a run that had lifted the stock more than 40% year to date.

While the guidance signaled confidence in the company's enrollment and operating leverage, some investors interpreted the disclosures as already priced in following the stock's strong second-quarter earnings beat and raised full-year outlook in early August. The lack of a fresh, near-term catalyst left the shares vulnerable to selling pressure.

Insider Selling and Elevated Short Interest

Sentiment has also been tempered by a steady cadence of insider transactions. Chief Executive Sean Duffy and other executives sold shares under pre-arranged Rule 10b5-1 trading plans in recent weeks, filings show, a pattern that can weigh on investor confidence even when the sales are part of routine equity-management programs. At the same time, OMDA carries a relatively high short interest of roughly 13% of shares, amplifying downward moves when momentum turns negative.

Sector and Macro Pressure

The decline also reflected broader market conditions. Growth-oriented digital health and healthcare technology peers have faced renewed pressure amid a risk-off tone in equities, with concerns around inflation, interest rates, and elevated energy prices weighing on smaller, higher-multiple names. OMDA, as a recently profitable but still richly valued virtual-care provider, has been particularly sensitive to shifts in risk appetite, a dynamic that contributed to the stock's decline on Friday.

Market Context and Trading Activity

The move pushed OMDA decisively below the psychologically important $20 level and beneath its 50-day moving average, which has acted as resistance during the recent pullback. The shares remain well above their 200-day average and their 52-week low of $10.28, underscoring that the long-term trend is still intact despite the near-term correction. Trading activity was elevated relative to the stock's roughly 1.2 million share average daily volume, indicating conviction behind the sell-off rather than a quiet drift lower.

What Comes Next for OMDA

Looking ahead, investors will monitor whether OMDA can stabilize above key support levels and whether the company continues to convert its expanding membership base into durable revenue and margin growth. The next earnings report is expected in early November, with analysts maintaining a broadly positive stance and a consensus "Moderate Buy" rating, though expectations have been tempered by the recent slide. Key risks include execution on new channel partnerships, ongoing insider selling, and the broader market's appetite for growth equities in an uncertain macro environment.

Trending AI Robots

For traders seeking a more systematic approach to navigating volatile markets, Tickeron's Trending AI Robots page offers a curated view of the platform's strongest-performing automated strategies. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the top performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving users a filtered look at what is working right now. Explore the Trending AI Robots to see which strategies are currently leading.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: OMDA

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


OMDA sees MACD Histogram just turned negative

OMDA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 10 instances where the indicator turned negative. In 8 of the 10 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OMDA as a result. In 14 of 20 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OMDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

The Aroon Indicator for OMDA entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +8.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where OMDA advanced for three days, in 74 of 89 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

OMDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.655) is normal, around the industry mean (4.523). P/E Ratio (22.522) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.908) is also within normal values, averaging (6.105).

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. OMDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OMDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -8%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 11%. CARL experienced the highest price growth at 21%, while DRIO experienced the biggest fall at -52%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was -2%. For the same stocks of the Industry, the average monthly volume growth was -6% and the average quarterly volume growth was -31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 53
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: -3 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Industry
N/A
Address
611 Gateway Boulevard
Phone
+1 888 987-8337
Employees
916
Web
https://www.omadahealth.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.